Search
SeaStar Medical Holding Corp
ICUAdd to Watchlist
4.650USD
+0.980+26.70%
Market hours （ET）Quotes delayed by 15 min
15.85MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+26.70%
5 Days
+34.01%
1 Month
+25.34%
6 Months
+93.75%
Year to Date
+93.75%
1 Year
+992.32%
Key Figures
3.700Open
4.740High
284.10KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
8.33%Turnover Ratio
3.670Prev. Close
3.700Low
666.65KTurnover
LossP/E Static
1.38P/B
0.00%Div Yield TTM
-126.18%ROA
13.00052wk High
6.43Volume Ratio
-24.83MNet Profit
3.41MShares
-55.1299EPS TTM
-1.03Beta
-302.01%ROE
2.07052wk Low
28.34%Amplitude
90.71%Gross Margin
15.85MMarket Cap
0.11Reward/Risk
7.38%Risk Rate
TradingKey Stock Score of SeaStar Medical Holding Corp
Currency: USD Updated: 2026-06-30Key Insights
SeaStar Medical Holding Corp's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 137 out of 204 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 10.00.In the medium term, the stock price is expected to trend down.Despite an average stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
SeaStar Medical Holding Corp's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
SeaStar Medical Holding Corp Highlights
StrengthsRisks
SeaStar Medical Holding Corporation is a commercial-stage medical technology company, which is focused on transforming treatments for critically ill patients facing organ failure and potential loss of life. The Company’s Selective Cytopheretic Device (SCD) is designed as a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation and creates a cascade of events that wreak havoc in the patient’s body. It has broad potential applications for patients suffering from both acute and chronic kidney disease as well as cardiovascular and other serious inflammatory diseases. Its SCD therapy is an extracorporeal synthetic membrane device designed to bind activated leukocytes (neutrophils and monocytes) when integrated into an existing continuous renal replacement therapy (CRRT) circuit in conjunction with the use of regional citrate anticoagulation (RCA).
Growing
The company is in a growing phase, with the latest annual income totaling USD 1.23M.
Overvalued
The company’s latest PE is -0.07, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 94.83K shares, decreasing 47.69% quarter-over-quarter.
Analyst Rating
Based on
1
analysts
Buy
Current Rating
10.000
Target Price
+181.69%
Upside Space
SeaStar Medical Holding Corp News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
SeaStar Medical Holding Corp Info
SeaStar Medical Holding Corporation is a commercial-stage medical technology company, which is focused on transforming treatments for critically ill patients facing organ failure and potential loss of life. The Company’s Selective Cytopheretic Device (SCD) is designed as a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation and creates a cascade of events that wreak havoc in the patient’s body. It has broad potential applications for patients suffering from both acute and chronic kidney disease as well as cardiovascular and other serious inflammatory diseases. Its SCD therapy is an extracorporeal synthetic membrane device designed to bind activated leukocytes (neutrophils and monocytes) when integrated into an existing continuous renal replacement therapy (CRRT) circuit in conjunction with the use of regional citrate anticoagulation (RCA).
Ticker SymbolICU
CompanySeaStar Medical Holding Corp
CEOSchlorff (Eric)
Websitehttps://seastarmedical.com
Related Instruments
+1.99%
+3.61%
+2.09%
+1.95%
+2.11%
+0.58%
+0.16%
+1.38%
+0.30%
+3.68%
+0.11%
+0.63%
+1.30%
+0.89%
+3.40%
+1.63%
+0.74%
+1.70%
+1.71%
+4.23%Popular Instruments
52710.700
+514.400 (+0.99%)
29989.600
-235.000 (-0.78%)
7518.900
+36.500 (+0.49%)
15380.000
-215.000 (-1.38%)
69936.000
-920.000 (-1.30%)
6291.200
-35.800 (-0.57%)
68.138
-1.783 (-2.55%)
295.410
+6.050 (+2.09%)
196.879
-3.211 (-1.60%)
4083.940
+76.660 (+1.91%)
FAQs
What is the current price of SeaStar Medical Holding Corp (ICU)?
The current price of SeaStar Medical Holding Corp (ICU) is 3.67.
What is the symbol of SeaStar Medical Holding Corp?
The ticker symbol of SeaStar Medical Holding Corp is ICU.
What is the 52-week high of SeaStar Medical Holding Corp?
The 52-week high of SeaStar Medical Holding Corp is 13.00.
What is the 52-week low of SeaStar Medical Holding Corp?
The 52-week low of SeaStar Medical Holding Corp is 2.07.
What is the market capitalization of SeaStar Medical Holding Corp?
The market capitalization of SeaStar Medical Holding Corp is 14.67M.
Is SeaStar Medical Holding Corp (ICU) currently rated as Buy, Hold, or Sell?
According to analysts, SeaStar Medical Holding Corp (ICU) has an overall rating of Buy, with a price target of 10.00.
What is the Earnings Per Share (EPS TTM) of SeaStar Medical Holding Corp (ICU)?
The Earnings Per Share (EPS TTM) of SeaStar Medical Holding Corp (ICU) is -58.61.